• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Garadacimab significantly reduces frequency of hereditary angioedema exacerbations

byJessie WillisandTeddy Guo
March 16, 2022
in Chronic Disease, Hematology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Garadacimab significantly reduced the number of monthly attacks in patients with hereditary angioedema compared to placebo.

2. No serious adverse events were observed in the treatment group with garadacimab.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Although relatively rare, hereditary angioedema is a debilitating disorder that leads to recurrent attacks of severe swelling in various parts of the body. A new potential prophylactic treatment for angioedema attacks is garadacimab, a monoclonal IgG antibody targeting activated FXII. In this randomized controlled trial, 32 patients were assigned to receive either placebo or 75 mg, 200 mg, or 600 mg of subcutaneous garadacimab. In a 12-week treatment period, the number of monthly attacks was greatly reduced in the garadacimab group compared to placebo with a 100% reduction in the 200 mg treatment group. Of note, garadacimab was well-tolerated with no serious adverse events. Limitations of this study include the small sample size, likely given the rareness of the disorder. Nonetheless, this study provides a potential option for prophylactic management of hereditary angioedema attacks.

Click to read the study in the Lancet

Relevant Reading: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update

In-Depth [randomized controlled trial]: This phase 2 trial took place across 12 research centers in four countries (Canada, Germany, Israel, and the USA). Inclusion criteria included patients with hereditary angioedema (HAE-C1-INH) aged 18-65 years. Patients enrolled were randomized 1:1:1:1 to either placebo, 75 mg, 200 mg, or 600 mg of subcutaneous garadacimab. The primary measured outcome was number of attacks per month experienced by patients. A total of 32 patients were randomized with a median age of 39.5 years with 56% female. During the 12-week treatment period, the rate of attacks was significantly reduced in the garadacimab groups compared to placebo. The median number of attacks was 4.6 in the placebo group, 0.0 with 75 mg, 0.0 with 200 mg, and 0.3 with 600 mg garadacimab. This translated to a 93% reduction in the 600 mg group (p=0.0003) and a 100% reduction in the 200 mg group (p=0.0002). There were no serious adverse events in either group, including no events of anaphylaxis, VTE, or bleeding.

RELATED REPORTS

The Scan by 2 Minute Medicine®: Tennis Legends, Sausage Fingers, Alopecia Awareness Month and Starbucks Recalls!

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: angioedemabradykininC1-inhibitor deficiencyEdemaGaradacimabhereditary angioedema
Previous Post

Low- and no-calorie sweetened beverages associated with reduced body weight compared to sugar-sweetened beverages: a systematic review and meta-analysis

Next Post

Wellness Check: Addictions

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Tennis Legends, Sausage Fingers, Alopecia Awareness Month and Starbucks Recalls!

September 20, 2022
#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema
StudyGraphics

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

April 13, 2022
Cardiology

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

March 22, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Infectious Disease

Development and validation of PEN-FAST clinical prediction tool for possible penicillin allergy

March 19, 2020
Next Post
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

Wellness Check: Addictions

Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ

Breast cancer overdiagnosis rates not as high as estimated previously

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options